Kezar Life Sciences, Inc.
Clinical trials sponsored by Kezar Life Sciences, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing treatments for autoimmune diseases and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug shows promise for liver disease in early trial
Disease control CompletedThis study tested a new drug called zetomipzomib in 24 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. Participants received either the drug or a placebo along with their usual treatment for 24 weeks, with an option to continue the drug fo…
Phase 2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental drug shows promise for rare muscle diseases
Disease control CompletedThis study tested the long-term safety and effectiveness of a drug called KZR-616 in 18 adults with active polymyositis or dermatomyositis, rare diseases that cause muscle inflammation and weakness. Participants who completed an earlier study received weekly injections of KZR-616…
Phase 2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug shows promise for lupus and kidney complications
Disease control CompletedThis study tested a new drug called KZR-616 (zetomipzomib) in 69 people with lupus, some of whom also had kidney inflammation (lupus nephritis). Participants received weekly injections for 13 or 24 weeks. The main goals were to check safety and see if the drug could reduce protei…
Phase 1/2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental drug KZR-616 tested for rare muscle disorders
Disease control CompletedThis Phase 2 trial tested a drug called KZR-616 (zetomipzomib) in 25 adults with active polymyositis or dermatomyositis, two rare diseases that cause muscle inflammation and weakness. Participants received either the drug or a placebo for 16 weeks, then switched to the other trea…
Phase 2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC